Fig. 6From: Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trialsComparison of brain recurrence between adjuvant first or third-generation of EGFR-TKIs versus adjuvant chemotherapy/placebo. A The risk of brain recurrence in intent-to-treat patients with regardless of the EGFR mutations status. B The risk of brain recurrence in patients harboring EGFR mutationsBack to article page